Finch Therapeutics Group Stock Net Income
| FNCH Stock | USD 13.74 0.01 0.07% |
As of the 4th of February, Finch Therapeutics shows the Coefficient Of Variation of 4249.23, mean deviation of 1.23, and Downside Deviation of 2.26. Finch Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.
Finch Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Finch Therapeutics' valuation are provided below:Finch Therapeutics Group does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Finch |
Finch Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Finch Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Finch Therapeutics.
| 11/06/2025 |
| 02/04/2026 |
If you would invest 0.00 in Finch Therapeutics on November 6, 2025 and sell it all today you would earn a total of 0.00 from holding Finch Therapeutics Group or generate 0.0% return on investment in Finch Therapeutics over 90 days. Finch Therapeutics is related to or competes with Celyad Oncology, Starpharma Holdings, Charlottes Web, and Positron Corp. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally admin... More
Finch Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Finch Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Finch Therapeutics Group upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.26 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 8.64 | |||
| Value At Risk | (3.44) | |||
| Potential Upside | 3.21 |
Finch Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Finch Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Finch Therapeutics' standard deviation. In reality, there are many statistical measures that can use Finch Therapeutics historical prices to predict the future Finch Therapeutics' volatility.| Risk Adjusted Performance | 0.0233 | |||
| Jensen Alpha | 0.0316 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.7104 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Finch Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Finch Therapeutics February 4, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0233 | |||
| Market Risk Adjusted Performance | 0.7204 | |||
| Mean Deviation | 1.23 | |||
| Semi Deviation | 1.57 | |||
| Downside Deviation | 2.26 | |||
| Coefficient Of Variation | 4249.23 | |||
| Standard Deviation | 1.85 | |||
| Variance | 3.43 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | 0.0316 | |||
| Total Risk Alpha | (0.07) | |||
| Sortino Ratio | (0) | |||
| Treynor Ratio | 0.7104 | |||
| Maximum Drawdown | 8.64 | |||
| Value At Risk | (3.44) | |||
| Potential Upside | 3.21 | |||
| Downside Variance | 5.11 | |||
| Semi Variance | 2.45 | |||
| Expected Short fall | (1.89) | |||
| Skewness | 0.0234 | |||
| Kurtosis | 0.4947 |
Finch Therapeutics Backtested Returns
Finch Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0113, which denotes the company had a -0.0113 % return per unit of risk over the last 3 months. Finch Therapeutics Group exposes twenty-seven different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Finch Therapeutics' Coefficient Of Variation of 4249.23, downside deviation of 2.26, and Mean Deviation of 1.23 to check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.0473, which means not very significant fluctuations relative to the market. As returns on the market increase, Finch Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Finch Therapeutics is expected to be smaller as well. At this point, Finch Therapeutics has a negative expected return of -0.0206%. Please make sure to confirm Finch Therapeutics' downside variance, day median price, and the relationship between the maximum drawdown and skewness , to decide if Finch Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.66 |
Very good reverse predictability
Finch Therapeutics Group has very good reverse predictability. Overlapping area represents the amount of predictability between Finch Therapeutics time series from 6th of November 2025 to 21st of December 2025 and 21st of December 2025 to 4th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Finch Therapeutics price movement. The serial correlation of -0.66 indicates that around 66.0% of current Finch Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.66 | |
| Spearman Rank Test | -0.43 | |
| Residual Average | 0.0 | |
| Price Variance | 0.11 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Finch Therapeutics Group reported net income of (74.75 Million). This is 121.9% lower than that of the Biotechnology sector and 206.72% lower than that of the Health Care industry. The net income for all United States stocks is 113.09% higher than that of the company.
Finch Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Finch Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics of similar companies.Finch Therapeutics is currently under evaluation in net income category among its peers.
Finch Fundamentals
| Return On Equity | -0.63 | |||
| Return On Asset | -0.22 | |||
| Current Valuation | 10.74 M | |||
| Shares Outstanding | 1.61 M | |||
| Shares Owned By Insiders | 53.48 % | |||
| Shares Owned By Institutions | 11.35 % | |||
| Number Of Shares Shorted | 19.2 K | |||
| Price To Book | 0.14 X | |||
| Price To Sales | 30.46 X | |||
| Revenue | 107 K | |||
| Gross Profit | (57.03 M) | |||
| EBITDA | (32.48 M) | |||
| Net Income | (74.75 M) | |||
| Cash And Equivalents | 104.67 M | |||
| Cash Per Share | 2.19 X | |||
| Total Debt | 30.13 M | |||
| Debt To Equity | 0.35 % | |||
| Current Ratio | 7.28 X | |||
| Book Value Per Share | 11.86 X | |||
| Cash Flow From Operations | (31.5 M) | |||
| Short Ratio | 0.19 X | |||
| Earnings Per Share | (6.59) X | |||
| Price To Earnings To Growth | (0.02) X | |||
| Target Price | 90.0 | |||
| Beta | 0.46 | |||
| Market Capitalization | 1.94 M | |||
| Total Asset | 71 M | |||
| Retained Earnings | (350.39 M) | |||
| Working Capital | 21.76 M | |||
| Net Asset | 71 M |
About Finch Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Finch Therapeutics Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Finch Pink Sheet
Finch Therapeutics financial ratios help investors to determine whether Finch Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Finch with respect to the benefits of owning Finch Therapeutics security.